| Name | Title | Contact Details |
|---|
At Senderra, Patients are people. It`s that simple. We are a specialty pharmacy, but that is where our work begins. We believe success lies in service to others. For this reason, we are dedicated to never losing sight of the people. We believe in the power of technology and data as catalysts to transform and improve processes. Technology is a tool to make our lives easier. For this reason, Senderra invests in our unique technology-driven platform in order to perform best at every turn. Finally, we believe in improved outcomes, no matter with whom we work. That includes Patients, Prescribers, Pharma and Payors. Improving outcomes means we strive to make the kinds of differences that matter.
Harvard Medtech`s mission is to solve pain and related afflictions by providing unmatched Tele-PainCare™ solutions that promote safe, effective healing holistically and organically in conjunction with, or preferably in lieu of, surgery and prescription pain medications. Our Vx Pain Relief Program uniquely integrates state-of-the-art Virtual Reality Therapy with Behavioral Health Clinicians, who regularly provide psychological and social interventions by telephone to patients in the comfort of their homes while keeping the prescribing physician apprised of the patient`s progress. Our FDA-registered, clinically validated, whole-person approach to delivering safe, effective, at-home care yields more complete, convenient, timely and affordable relief of pain, depression, anxiety and related afflictions while requiring zero investment by the prescribing physician.
National Institute of Clinical Research is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lipo Chemicals is a Paterson, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.